You Can Thank Private Equity for That Enormous Doctor's Bill

Role of Private Equity (PE) in Healthcare

• Many see PE as a “maggot infestation”: it exploits already‑broken structures by loading practices with debt, cutting staff, over‑prescribing or upselling, and jacking up prices for inelastic, life‑or‑death services.
• Others argue PE is a symptom, not root cause: it thrives where regulation, market design, and monopoly power already create easy rents.
• Examples of similar PE “strip mining” are cited in restaurants, retail, supermarkets, housing, and auto repair, not just healthcare.

Structural Problems in US Healthcare

• Strong consensus that no single “boogeyman” explains costs; instead, a tangle of incentives across insurers, providers, drug companies, and regulators.
• Insurance is repeatedly blamed: employer‑tied coverage, opaque negotiated rates, narrow networks, and “cost plus” design that removes price discipline.
• Patients describe pervasive billing chaos, “mistakes” that favor providers, and huge time costs to contest small overcharges.

Supply, Regulation, and Labor Constraints

• Commenters highlight artificial supply limits: residency caps funded by Medicare, certificate‑of‑need laws, and professional gatekeeping.
• There is debate over whether increasing the number of doctors (and using more NPs/PAs) is feasible without worsening burnout or training quality.
• Some argue primary care is structurally underpaid vs. specialties, skewing career choices.

Comparisons and System Models

• Many note other rich countries (single‑payer or regulated multi‑payer) spend far less with equal or better outcomes; some advocate socialized or at least public‑option baselines.
• Others emphasize that even those systems face wait times, underinvestment, or their own political constraints.

Reform Ideas

• Proposals include:
  • Medicare drug price negotiation expansion and stronger antitrust/FTC action.
  • Public, non‑profit insurer open to all (leveraging existing federal programs).
  • Direct primary care / concierge models to bypass insurers.
  • Transparency in pricing, banning direct insurer–provider payments, limiting pharma ads, and industrial policy for domestic drug/device production.

Broader Political and Ideological Debate

• Thread is polarized on capitalism, government regulation, and party politics.
• Some blame “corrupt capitalism” and campaign finance; others blame over‑regulation and captured bureaucracies.
• There is agreement that lobbying by insurers, hospitals, and pharma entrenches the status quo, regardless of formal system design.